Active surveillance for low-risk prostate cancer: Selection of patients and predictors of progression

Nature Clinical Practice Urology

Volumn 5, Issue 5, 2008, Pages 277-283

  Dall'Era, Marc A ^a   Konety, Badrinath R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COHORT ANALYSIS; DIGITAL RECTAL EXAMINATION; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HUMAN; LIFESTYLE MODIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATIENT COUNSELING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PSYCHOSOCIAL CARE; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; WATCHFUL WAITING;

BIOPSY; DECISION MAKING; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; MALE; PATIENT SELECTION; PHYSICAL EXAMINATION; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 43449110157     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1058     Document Type: Review

References (50)

1. Jemal A et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Johansson JE et al. (2004) Natural history of early, localized prostate cancer. JAMA 291: 2713-2719
3. Albertsen PC et al. (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 2095-2101
4. Yatani R et al. (1982) Geographic pathology of latent prostatic cardnoma. Int J Cancer 29, 611-616
5. Draisma G et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878
6. Etzioni R et al. (2002) Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94: 981-990
7. Breslow N et al. (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20: 680-688
8. Byar DP and Mostofi FK (1969) Cancer of the prostate in men less than 50 years old: An analysis of 51 cases. J Urol 102: 726-733
9. Guileyardo, JM et al. (1980) Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 65: 311-316
10. Rullis I et al. (1975) Incidence of prostatic carcinoma in the elderly. Urology 6: 295-297
11. Wei JT et al. (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20: 557-566
12. Litwin MS et al. (2007) Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109: 2239-2247
13. Epstein JI et al. (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374
14. Greens KL et al. (2006) Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CaPSURE. J Urol 175: 125-129
15. Roemeling S et al. (2006) Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50: 475-482
16. Carter HB et al. (2002) Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol 167: 1231-1234
17. Venkitaraman R et al. (2008) Prostate-specific antigen velocity in untreated, localized prostate cancer. BJU Int 101: 161-164
18. Klotz L (2006) Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24: 46-50
19. Emiliozzi P et al. (2004) Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol 172: 2224-2226
20. Vashi AR et al. (1998) A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 159: 920-924
21. Epstein JI et al. (1997) Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 158 1886-1890
22. Partin AW et al. (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58: 843-848
23. D'Amico AV et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974
24. Kattan MW et al. (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771
25. Cooperberg MR et al. (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor or disease recurrence after radical prostatectomy. J Urol 173: 1938-1942
26. Steyerberg EW et al. (2007) Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 177: 107-112
27. Kattan MW et al. (2003) Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170: 1792-1797
28. Roemeling S et al. (2007) Nomogram use for the prediction of indolent prostate cancer: Impact on screen-detected populations. Cancer 110: 2218-2221
29. Wilt TJ and Brawer MK (1997) The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Williston Park) 11: 1133-1139
30. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135
31. D'Amico AV et al. (2005) Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294: 440-447
32. Freedland SJ et al. (2006) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439
33. Carter CA et al. (2003) Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21: 4001-4008
34. Ali K et al. (2007) PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120: 170-174
35. Stephenson AJ et al. (2002) Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59. 652-656
36. Epstein JI et al. (2001) Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166: 1688-1691
37. Patel MI et al. (2004) An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171: 1520-1524
38. Carter HB et al. (2007) Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178: 2359-2364
39. Coakley FV et al. (2003) Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170: S69-75
40. Shukla-Dave A et al. (2007) The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99: 786-793
41. Loch T (2007) Urologic imaging for localized prostate cancer in 2007. World J Urol 25: 121-129
42. Meng MV et al. (2003) Predictors of treatment after initial surveillance in men with prostate cancer: Results from CaPSURE. J Urol 170: 2279-2283
43. Roemeling S et al. (2006) Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 1244-1250
44. Hardie C et al. (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95: 956-960
45. Klotz L (2005) Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2: 136-142
46. Martin RM et al. (2006) Continuing controversy over monitoring men with localized prostate cancer: A systematic review of programs in the prostate specific antigen era. J Urol 176: 439-449
47. Latini DM et al. (2007) The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178: 826-831
48. Wallace M (2003) Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 30: 303-309
49. Balley DE et al. (2004) Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 27: 339-346
50. Ornish D et al. (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174: 1065--1069